Xuanzhu Biopharmaceutical Co., Ltd. (2575), an innovative pharmaceutical company rooted in China with a global perspective, has been included as a constituent of the Hang Seng Composite Index. According to the results of the quarterly review of the Hang Seng Family of Indexes for the period ended December 31, 2025, announced on February 13, 2026, the adjustment will take effect on March 9, 2026.

The Hang Seng Composite Index covers the top 95% of companies listed on the Main Board of the Hong Kong Stock Exchange by cumulative market capitalization. Consequently, Xuanzhu Biopharm’s inclusion is expected to make its shares eligible for trading under both the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect, thus providing additional channels for investors in both markets.

The board of directors stated that this inclusion is likely to enhance Xuanzhu Biopharm’s share liquidity, broaden its investor base, and address the unmet major clinical needs in digestion, oncology, and non-alcoholic steatohepatitis. The company specializes in researching, developing, producing, and commercializing Class 1 new drugs with proprietary intellectual property, supported by two research and development platforms focused on small molecule chemistry and large molecule biopharmaceuticals.

Shareholders and potential investors are advised to exercise caution when dealing in the securities of Xuanzhu Biopharm. The board expressed gratitude to all shareholders, investors, and partners for their long-standing support and reaffirmed the company’s commitment to further growth and value creation.